Novel agents in myeloma: an exciting saga.
Mark
Tomer
T
Division of Hematology and Medical Oncology, Department of Medicine, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.
Niesvizky
Ruben
R
Coleman
Morton
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control
D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide